For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.
An Open-Label Randomized Active- Controlled Phase Ii Clinical Study To Assess The Efficacy And Safety Of Afuresertib Plus Paclitaxel Versus Paclitaxel In Patients With Platinum-Resistant Ovarian Cancer
To evaluate the efficacy of afuresertib in combination with paclitaxel when compared to paclitaxel alone in patients with platinum-resistant ovarian cancer.
DiagnosisPatients who have platinum-resistant ovarian cancer.
Platinum resistant ovarian cancer. Measurable disease.
1 to 3 prior chemotherapies
No more than 1 in the platinum resistant setting.
Must have prior use of bevacizumab (unless contraindicated).
Tumor tissue within 1 year or fresh biopsy.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
Patients will be assigned to one of the two treatment arms:
Group 1: Patients will receive combination treatment of afuresertib in combination with paclitaxel.
Group 2: Patients will receive treatment with only paclitaxel.
For more information, visit Clinicaltrials.gov